Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.

Anna GrendaJustyna BłachMichał SzczyrekPaweł KrawczykMarcin NicośBarbara Kuźnar KamińskaMonika JakimiecGrażyna BalickaIzabela ChmielewskaHalina Batura-GabryelMarek SawickiJanusz Milanowski

Published in: Cancer medicine (2019)

Polymorphisms of the TOP2A and ERCC1 genes may be a predictive factor of toxicities and survival for chemotherapy in NSCLC patients.

Keyphrases

end stage renal disease
genome wide
small cell lung cancer
ejection fraction
dna repair
chronic kidney disease
locally advanced
dna methylation
gene expression
stem cells
bioinformatics analysis
radiation therapy
patient reported outcomes
brain metastases